Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro

Pharmaceutical excipients are no longer considered inert and have been shown to influence the activity of metabolic enzymes and transporters, resulting in altered pharmacokinetics of substrate drugs. In this study, the effect of 25 excipients commonly used in drug formulations were investigated for their effect on P-glycoprotein (P-gp) activity. The effect of excipients on P-gp were assessed by measuring the change in the cellular accumulation of a P-gp substrate, digoxin, in MDCK-MDR1 (Madin Darby canine kidney transfected with multidrug resistance 1 gene) cells. The cells were exposed to low (10 mu M) and high (200 mu M) concentrations of excipient along with 10 mu M digoxin. Excipient concentrations were chosen to span the range of concentrations previously used for investigating activities in vitro. At 10 mu M of excipient, an increase in the intracellular digoxin concentration was seen with D-alpha-tocopherol poly-(ethylene glycol) succinate (Vit-E-PEG; p = 0.002), poly(ethylene oxide)(20) sorbitan monooleate (Tween 80; p = 0.001), cetyltrimethylammonium bromide (CTAB; p = 0.021), poly(ethylene oxide)(35) modified castor oil (Cremophor EL; p = 0.01), polyethylene glycol(15)-hydroxystearate (Solutol HS 15; p = 0.006), and poly(ethylene glycol) hexadecyl ether (Brij 58; p = 0.001). At 200 mu M, Vit-E-PEG (p < 0.0001), sodium 1,4-bis (2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate (AOT; p < 0.0001), Tween 80 (p < 0.0001), CTAB (p = 0.004), poly(ethylene oxide)20 sorbitan monolaurate (Tween 20; p < 0.0001), Cremophor EL (p < 0.0001), Solutol HS 15 (p < 0.0001), Brij 58 (p < 0.0001), and sodium carboxymethyl cellulose (NaCMC; p = 0.006) increased intracellular digoxin significantly. Concentration-dependent inhibition of P-gp was then investigated for selected excipients giving an IC50 for Vit-E-PEG (12.48 mu M), AOT (192.5 mu M), Tween 80 (45.29 mu M), CTAB (96.67 mu M), Tween 20 (74.15 mu M), Cremophor EL (11.92 mu M), Solutol HS 15 (179.8 mu M), Brij 58 (25.22 mu M), and NaCMC (46.69 mu M). These data add to the growing body of evidence demonstrating that not all excipients are inert and will aid excipient choice for rational formulation development.